Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
Kohei Shitara, Jaffer A. Ajani, Markus Hermann Moehler, Marcelo Garrido S, Carlos Gallardo, Lin Shen, Kensei Yamaguchi, Lucjan Stanislaw Wyrwicz, Tomasz Skoczylas, Arinilda Silva Campos Bragagnoli, Tianshu Liu, Mustapha Ali Tehfe · 2022
Read Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer by Kohei Shitara, Jaffer A. Ajani, Markus Hermann Moehler, Marcelo Garrido S, Carlos Gallardo, Lin Shen, Kensei Yamaguchi, Lucjan Stanislaw Wyrwicz, Tomasz Skoczylas, Arinilda Silva Campos Bragagnoli, Tianshu Liu, Mustapha Ali Tehfe (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w4220909053.txt.
Description
Kohei Shitara, Jaffer Ajani, Markus Moehler, and colleagues report a large trial of immunotherapy for gastro-oesophageal cancer, in Nature in 2022. Patients had advanced cancer of the stomach, the junction with the food pipe, or the food pipe itself. The trial tested the drug nivolumab, which frees immune cells to attack tumours. It was given with chemotherapy, or with a second immune drug, ipilimumab.
Patients were assigned at random to each treatment or to chemotherapy alone between 2016 and 2019. The nivolumab plus ipilimumab arm was closed early, after more side effects and early deaths than the other arms. Nivolumab plus chemotherapy improved overall survival over chemotherapy alone. Results like these reshaped first treatment for this hard-to-treat cancer group.
Catalog record
| CREATOR | Kohei Shitara, Jaffer A. Ajani, Markus Hermann Moehler, Marcelo Garrido S, Carlos Gallardo, Lin Shen, Kensei Yamaguchi, Lucjan Stanislaw Wyrwicz, Tomasz Skoczylas, Arinilda Silva Campos Bragagnoli, Tianshu Liu, Mustapha Ali Tehfe |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 71 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | OpenAlex / Nature |